UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

Clinical cancer research, 2022-07, Vol.28 (14), p.3032-3041

2022

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies

Cancer chemotherapy and pharmacology, 2022-03, Vol.89 (3), p.373-382

2022

Volltextzugriff (PDF)

Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment

Genetics in medicine, 2015-12, Vol.17 (12), p.962-964

2015

Volltextzugriff (PDF)

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1

JNCI : Journal of the National Cancer Institute, 2016-04, Vol.108 (4), p.djv365

2016

Volltextzugriff (PDF)

Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome

The Journal of clinical investigation, 2017-01, Vol.127 (1), p.132-136

2017

Volltextzugriff (PDF)

Hereditary Cancer Syndromes as Model Systems for Chemopreventive Agent Development

Seminars in oncology, 2016-02, Vol.43 (1), p.134-145

2016

Volltextzugriff (PDF)

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2020-10, Vol.8 (2), p.e001095

2020

Volltextzugriff (PDF)

The Affordable Care Act and genetic testing for inheritable cancer syndromes: impact on high-risk underserved minorities

Journal of health care for the poor and underserved, 2014-02, Vol.25 (1 Suppl), p.46-62

2014

Volltextzugriff (PDF)

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Journal for immunotherapy of cancer, 2019-08, Vol.7 (1), p.225-225, Article 225

2019

Volltextzugriff (PDF)

Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome

JNCI cancer spectrum, 2020-12, Vol.4 (6), p.pkaa063-pkaa063

2020

Volltextzugriff (PDF)

A centralized, primary care medical home survivorship model at the GW Cancer Center

Journal of clinical oncology, 2018-03, Vol.36 (7_suppl), p.45-45

2018

Volltextzugriff (PDF)

Effect of metformin chemoprevention on metabolomics profiles in Li-Fraumeni Syndrome (LFS)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1556-1556

2017

Volltextzugriff (PDF)

A View on Drug Development for Cancer Prevention

Cancer discovery, 2023-05, Vol.13 (5), p.1058-1083

2023

Volltextzugriff (PDF)

Adult cancer survivorship referrals for hereditary cancer genetic testing

Journal of clinical oncology, 2018-03, Vol.36 (7_suppl), p.183-183

2018

Volltextzugriff (PDF)

Genetic and environmental determinants on tissue response to in vitro carcinogen exposure and risk of breast cancer

Cancer research (Chicago, Ill.), 2002-08, Vol.62 (16), p.4566-4570

2002

Volltextzugriff (PDF)

A Case-Control Study of Dietary Phytoestrogens and Testicular Cancer Risk

Nutrition and cancer, 2002-01, Vol.44 (1), p.44-51

2002

Volltextzugriff (PDF)

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.26-27

2020

Volltextzugriff (PDF)

Vasomotor symptoms, BMI, and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.1501-1501

2015

Volltextzugriff (PDF)

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1

JNCI : Journal of the National Cancer Institute, 2016-04, Vol.108 (4), p.1

2016

Volltextzugriff (PDF)

Abstract CT156: Safety and tolerability of metformin for chemoprevention in Li-Fraumeni syndrome (LFS)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT156-CT156

2016

Volltextzugriff (PDF)

Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.1512-1512

2014

Volltextzugriff (PDF)

Abstract 1383: Li-Fraumeni syndrome: Clinical experience with family psycho-social issues

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1383-1383

2013

Volltextzugriff (PDF)

Abstract 29: Design of a phase I chemoprevention study of metformin and Li-Fraumeni syndrome (LFS)

Cancer research (Chicago, Ill.), 2014-12, Vol.74 (23_Supplement), p.29-29

2014

Volltextzugriff (PDF)

Telomere length and risk of glioma

Cancer epidemiology, 2013-12, Vol.37 (6), p.935-938

2013

Volltextzugriff (PDF)

Abstract A23: Cancer outcomes in the diabetes prevention program outcomes study

Cancer prevention research (Philadelphia, Pa.), 2015-10, Vol.8 (10_Supplement), p.A23-A23

2015

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma

Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies

Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1

Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome

Hereditary Cancer Syndromes as Model Systems for Chemopreventive Agent Development

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

The Affordable Care Act and genetic testing for inheritable cancer syndromes: impact on high-risk underserved minorities

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome

A centralized, primary care medical home survivorship model at the GW Cancer Center

Effect of metformin chemoprevention on metabolomics profiles in Li-Fraumeni Syndrome (LFS)

A View on Drug Development for Cancer Prevention

Adult cancer survivorship referrals for hereditary cancer genetic testing

Genetic and environmental determinants on tissue response to in vitro carcinogen exposure and risk of breast cancer

A Case-Control Study of Dietary Phytoestrogens and Testicular Cancer Risk

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Vasomotor symptoms, BMI, and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1)

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1

Abstract CT156: Safety and tolerability of metformin for chemoprevention in Li-Fraumeni syndrome (LFS)

Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial

Abstract 1383: Li-Fraumeni syndrome: Clinical experience with family psycho-social issues

Abstract 29: Design of a phase I chemoprevention study of metformin and Li-Fraumeni syndrome (LFS)

Telomere length and risk of glioma

Abstract A23: Cancer outcomes in the diabetes prevention program outcomes study

Suchergebnisse filtern